WILEX AG Company Profile
WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging from research to late stage clinical development. The company has two therapeutic platforms: antibodies, which specifically target the tumor cells, and small molecules, which block metastasis and primary tumor growth.
Currently, WILEX has three drug candidates in clinical development. The lead compound Rencarex® (WX-G250), a targeted antibody therapy for the treatment of solid tumors, is currently in a pivotal clinical Phase III trial as an adjuvant treatment of non-metastatic renal cell cancer (RCC). The company’s non-cytotoxic uPA and serine protease inhibitors WX-UK1 and WX-671, which are in clinical development, are assigned for the anti-metastatic treatment of breast cancer and other solid tumors. The company’s pre-clinical research pipeline currently consists of two projects.
WILEX was founded in 1997 by clinical oncologists from the Technical University of Munich.
Location
Grillparzerstr. 16
Munich
81675
Germany
Contact
Phone: 49 (0)89 41 31 38 0
Fax: 49 (0)89 41 31 38 99
Email: investors@wilex.com
News Articles
WILEX AG: WILEX Inc. schließt Vertriebsvereinbarung mit Immundiagnostik AG für D-A-CH Region ab
WILEX AG: WILEX Inc. schließt Vertriebsvereinbarung mit Immundiagnostik AG für D-A-CH Region ab DGAP-News: WILEX AG / Schlagwort(e): Kooperation WILEX AG: WILEX Inc. schließt Vertriebsvereinbarung....
DGAP-Stimmrechte: WILEX AG (deutsch)
WILEX AG: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung WILEX AG 17.12.2012 18:02 Veröffentlichung einer Stimmrechtsmitteilung, übermittelt durch die DGAP - e...
Wilex CFO Llewellyn-Davies to depart
Wilex AG (Xetra:WL6) said Peter Llewellyn-Davies will depart as CFO, effective Sept. 1. He will be replaced by Jan Schmidt-Brand, who is managing director of Wilex's Heidelberg Pharma GmbH subsidiary....
Wilex AG (Xetra:WL6) raised EUR 16.1 million ($19.9 million) through the sale of 4.4 million shares at EUR 3.70 in a rights offering. The price is a 1% discount to Wilex's close of EUR 3.74 on Aug. 2,...
Wilex: Entlassungen nach Fehlschlag
Bei der Münchner Wilex AG wird gespart anstatt gefeiert. Das schmerzhafte Scheitern des...
Wilex: Kapitalerhöhung und Vorstandswechsel
Die Wilex AG beruft einen neuen Finanzvorstand. Jan Schmidt-Brandt wird zum 1. September das Amt...
Wilex planning rights offering
Wilex AG (Xetra:WL6) said it is planning to raise up to EUR 25 million ($30.8 million) through the sale of up to 6.8 million shares at EUR 3.70 million in a rights offering. The price is a 1% discount...
DGAP-HV: Wilex AG: Bekanntmachung der Einberufung -2-
DJ DGAP-HV: Wilex AG: Bekanntmachung der Einberufung zur Hauptversammlung am 14.06.2013 in München mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG DGAP-HV: Wilex AG / Bekanntmachung der...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connect...
More Information about "WILEX AG" on BioPortfolio
We have published hundreds of WILEX AG news stories on BioPortfolio along with dozens of WILEX AG Clinical Trials and PubMed Articles about WILEX AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of WILEX AG Companies in our database. You can also find out about relevant WILEX AG Drugs and Medications on this site too.
